 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Economic Model Finds MammaPrint More Cost-Effective than Oncotype; Highlights Need for Future Studies
May 09, 2012
Economic Model Finds MammaPrint More Cost-Effective than Oncotype; Highlights Need for Future Studies
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- In Preliminary Recommendation, UK's NICE Backs Oncotype DX in Subset of Breast Cancer Patients
February 20, 2013 / Pharmacogenomics Reporter - After Moving MammaPrint to FFPE Format, Agendia Sees Revenue Boost, Increasing Adoption
April 25, 2012 / Pharmacogenomics Reporter - Breast Cancer Test Makers Will Attempt to Sway UK's NICE in Wake of Initial Negative Opinion
February 8, 2012 / Pharmacogenomics Reporter - St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011 / Pharmacogenomics Reporter - Genomic Health Study Highlights Discrepancy between Oncotype DX and MammaPrint Results
December 19, 2012 / Pharmacogenomics Reporter